From blockbuster to nichebuster

Two decades of EU market protection of ‘orphan’ (rare disease) medicines have greatly benefitted the industry. According to research by The Investigative Desk, published in the British Medical Journal (BMJ) and the Dutch Journal of Medicine (NTvG), many of these ‘orphan medicines’ make billions of euros. Twenty years ago, the European Commission introduced a legislation […]

From blockbuster to nichebuster Read More »